109 related articles for article (PubMed ID: 23007573)
1. Impact of biomarkers on clinical trial risk in breast cancer.
Parker JL; Lushina N; Bal PS; Petrella T; Dent R; Lopes G
Breast Cancer Res Treat; 2012 Nov; 136(1):179-85. PubMed ID: 23007573
[TBL] [Abstract][Full Text] [Related]
2. Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancer.
Modi S; DiGiovanna MP; Lu Z; Moskowitz C; Panageas KS; Van Poznak C; Hudis CA; Norton L; Tan L; Stern DF; Carter D; Seidman AD
Cancer Invest; 2005; 23(6):483-7. PubMed ID: 16203655
[TBL] [Abstract][Full Text] [Related]
3. Capecitabine after anthracycline and taxane exposure in HER2-negative metastatic breast cancer patients: response, survival and prognostic factors.
Gilabert M; Bertucci F; Esterni B; Madroszyk A; Tarpin C; Jacquemier J; Extra JM; Viens P; Gonçalves A
Anticancer Res; 2011 Mar; 31(3):1079-86. PubMed ID: 21498742
[TBL] [Abstract][Full Text] [Related]
4. HER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancer.
Kim JW; Kim JH; Im SA; Kim YJ; Han HS; Kim JS; Lee KH; Kim TY; Han SW; Jeon YK; Oh DY; Kim TY; Park IA
Cancer Chemother Pharmacol; 2013 Jul; 72(1):109-15. PubMed ID: 23673443
[TBL] [Abstract][Full Text] [Related]
5. Biomarkers and receptor targeted therapies reduce clinical trial risk in non-small-cell lung cancer.
Falconi A; Lopes G; Parker JL
J Thorac Oncol; 2014 Feb; 9(2):163-9. PubMed ID: 24419412
[TBL] [Abstract][Full Text] [Related]
6. Evidence-based use of neoadjuvant taxane in operable and inoperable breast cancer.
Estévez LG; Gradishar WJ
Clin Cancer Res; 2004 May; 10(10):3249-61. PubMed ID: 15161677
[TBL] [Abstract][Full Text] [Related]
7. Cost comparison of capecitabine in patients with breast cancer.
Rugo HS; Kohles J; Schulman KL
Am J Clin Oncol; 2010 Dec; 33(6):550-6. PubMed ID: 20051811
[TBL] [Abstract][Full Text] [Related]
8. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial.
Untch M; Loibl S; Bischoff J; Eidtmann H; Kaufmann M; Blohmer JU; Hilfrich J; Strumberg D; Fasching PA; Kreienberg R; Tesch H; Hanusch C; Gerber B; Rezai M; Jackisch C; Huober J; Kühn T; Nekljudova V; von Minckwitz G; ;
Lancet Oncol; 2012 Feb; 13(2):135-44. PubMed ID: 22257523
[TBL] [Abstract][Full Text] [Related]
9. The role of anthracyclines in the treatment of early breast cancer.
Greene J; Hennessy B
J Oncol Pharm Pract; 2015 Jun; 21(3):201-12. PubMed ID: 24769570
[TBL] [Abstract][Full Text] [Related]
10. [Chemotherapy for breast cancer refractory to anthracycline, taxane or trastuzumab].
Ito Y; Kobayashi K
Gan To Kagaku Ryoho; 2009 May; 36(5):726-9. PubMed ID: 19461171
[TBL] [Abstract][Full Text] [Related]
11. Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31.
Gelmon KA; Boyle FM; Kaufman B; Huntsman DG; Manikhas A; Di Leo A; Martin M; Schwartzberg LS; Lemieux J; Aparicio S; Shepherd LE; Dent S; Ellard SL; Tonkin K; Pritchard KI; Whelan TJ; Nomikos D; Nusch A; Coleman RE; Mukai H; Tjulandin S; Khasanov R; Rizel S; Connor AP; Santillana SL; Chapman JA; Parulekar WR
J Clin Oncol; 2015 May; 33(14):1574-83. PubMed ID: 25779558
[TBL] [Abstract][Full Text] [Related]
12. Lessons learned from independent central review.
Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of first-line bevacizumab combined with taxane therapy in Chinese patients with HER2-negative locally recurrent or metastatic breast cancer: findings from the ATHENA study.
Xu BH; Jiang ZF; Shen ZZ; Guan ZZ; Chen ZD; Cheng Y; Zheng H; Jiang J; Wang XJ; Tong ZS; Qin SK; Luo Y; Yao M; Wang LW; He J
Chin Med J (Engl); 2012 Mar; 125(5):764-9. PubMed ID: 22490570
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.
Krop IE; LoRusso P; Miller KD; Modi S; Yardley D; Rodriguez G; Guardino E; Lu M; Zheng M; Girish S; Amler L; Winer EP; Rugo HS
J Clin Oncol; 2012 Sep; 30(26):3234-41. PubMed ID: 22649126
[TBL] [Abstract][Full Text] [Related]
15. The clinical significance of Ki-67 as a marker of prognostic value and chemosensitivity prediction in hormone-receptor-positive breast cancer: a meta-analysis of the published literature.
Liu Y; Yin W; Yan T; Du Y; Shao Z; Lu J
Curr Med Res Opin; 2013 Nov; 29(11):1453-61. PubMed ID: 23927551
[TBL] [Abstract][Full Text] [Related]
16. Pyrotinib: First Global Approval.
Blair HA
Drugs; 2018 Nov; 78(16):1751-1755. PubMed ID: 30341682
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular risk profile of patients with HER2/neu-positive breast cancer treated with anthracycline-taxane-containing adjuvant chemotherapy and/or trastuzumab.
Jones LW; Haykowsky M; Peddle CJ; Joy AA; Pituskin EN; Tkachuk LM; Courneya KS; Slamon DJ; Mackey JR
Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):1026-31. PubMed ID: 17507633
[TBL] [Abstract][Full Text] [Related]
18. Updates in anti-HER2 combination therapy.
Burstein H
Clin Adv Hematol Oncol; 2008 Dec; 6(12):873-4. PubMed ID: 19209136
[No Abstract] [Full Text] [Related]
19. Role of anthracyclines in the treatment of early breast cancer.
Gianni L; Norton L; Wolmark N; Suter TM; Bonadonna G; Hortobagyi GN
J Clin Oncol; 2009 Oct; 27(28):4798-808. PubMed ID: 19687331
[TBL] [Abstract][Full Text] [Related]
20. Cost effectiveness of ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.
Reed SD; Li Y; Anstrom KJ; Schulman KA
J Clin Oncol; 2009 May; 27(13):2185-91. PubMed ID: 19332722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
